ClinicalTrials.gg
RecruitingNCT06254001Updated Feb 23, 2024

Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects

A Phase 4 interventional study of Bupropion and Nicotine replacement therapy (Nicotine patches) in Tobacco Smoking, Tobacco Withdrawal and Nicotine Addiction, sponsored by National Institute of Respiratory Diseases, Mexico. Recruiting at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by National Institute of Respiratory Diseases, Mexico · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In the 20th century, tobacco caused the death of 100 million people worldwide and it is estimated that it will be responsible for 1 billion deaths in the 21st century. Currently 8 million people die each year from smoking, 7 million are associated with active smoking, thus being the main risk factor for loss of disability-adjusted life years for men and the ninth most important risk factor for women. In previous studies it has been reported that approximately 21% (14%-30%) of subjects who have required hospitalization are active smokers, being higher in men than in women (28% vs 14%). The initiation of treatment for smoking cessation in this group of subjects has shown an effectiveness rate of up to 65% to maintain abstinence 6 to 12 months after discharge. The effectiveness has been analyzed in scenarios with only brief advice, in some others with the use of medications such as varenicline, bupropion and nicotine replacement therapy, however, the interventions have not been standardized for adequate analysis, which could contribute to the different results.

Read the detailed description

The objective is to know the effectiveness of combined treatment to maintain abstinence in participants with active smoking who are hospitalized in a reference center.

Bupropion and nicotine replacement therapy are the drugs used in this clinical trial.

Participants will be randomly assigned to two groups: nicotine replacement therapy or nicotine replacement therapy plus bupropion. All participants will have counseling, conductive behavioral therapy, follow-up at 3, 6 and 12 months with a pulmonologist. Pulmonary function tests will be performed every 3, 6, and 12 months. Abstinence will be corroborated with a cotinine (urine) test and an exhaled carbon monoxide test.

02

Conditions studied

  • Tobacco Smoking
  • Tobacco Withdrawal
  • Nicotine Addiction
  • Nicotine Withdrawal
  • Nicotine Replacement Therapy

Keywords

  • tobacco
  • bupropion
  • nicotine replacement therapy
  • abstinence
03

In context

Tobacco Smoking

265 studies on the registry are indexed under Tobacco Smoking; 43 are open to participants now.

This study's planned enrollment of 134 is above the median of 120 across 230 interventional studies indexed under Tobacco Smoking.

Browse Tobacco Smoking studies →

Lead sponsor

National Institute of Respiratory Diseases, Mexico is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

>18 years Active smokers (consumption of more than 100 cigarettes in their entire life, and who have consumed cigarettes in the last 30 days) Hospitalized subjects

Exclusion criteria

Exclusion Criteria:

  • Subjects who have had pharmacological treatment to stop smoking in the last month
  • Subjects with for medications.

Sample size calculation, 80% power, unilateral, due to difference in proportions, estimated loss of 25%.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (estimated)

Study arms

  • Active comparator
    Nicotine replacement therapy

    Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy

    Drug: Nicotine replacement therapy (Nicotine patches)

  • Experimental
    Nicotine replacement therapy and Bupropion

    Nicotine replacement therapy (Nicotine patches) plus Bupropion and counseling and cognitive behavioral therapy

    Drug: Bupropion · Drug: Nicotine replacement therapy (Nicotine patches)

Interventions

  • Bupropion will be added at doses of 150 mg to 300 mg per day in addition to nicotine replacement therapy, counseling and cognitive behavioral therapy

  • DrugNicotine replacement therapy (Nicotine patches)

    Nicotine replacement therapy (Nicotine patches) plus counseling and cognitive behavioral therapy

06

What researchers measure

Primary outcomes

  1. Abstinence at 12 months. Negative cotinine test and negative an exhaled carbon monoxide test

    Abstinence will be corroborated with a cotinine test and an exhaled carbon monoxide test. Negative urine cotinine test and an exhaled carbon monoxide test less than 6 ppb.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Martinez C, Fu M, Castellano Y, Riccobene A, Fernandez P, Cabrera S, Gavilan E, Feliu A, Puig-Llobet M, Fuster P, Martinez-Sanchez JM, Montes J, Estrada JM, Moreno C, Falco-Pegueroles A, Galimany J, Brando C, Suner-Soler R, Capsada A, Fernandez E; y Grupo de Coordinadores de la Red Catalana de Hospitales sin Humo (XCHsF). Smoking among hospitalized patients: A multi-hospital cross-sectional study of a widely neglected problem. Tob Induc Dis. 2018 Jul 30;16:34. doi: 10.18332/tid/92927. eCollection 2018. PubMed 31516433 ↗
  • Rigotti NA, Clair C, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2012 May 16;5(5):CD001837. doi: 10.1002/14651858.CD001837.pub3. PubMed 22592676 ↗
  • Makate M, Whetton S, Tait RJ, Dey T, Scollo M, Banks E, Norman R, Pidd K, Roche AM, Allsop S. Tobacco Cost of Illness Studies: A Systematic Review. Nicotine Tob Res. 2020 Apr 17;22(4):458-465. doi: 10.1093/ntr/ntz038. PubMed 30874290 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data will be collected on the redCap platform, and may be shared in Excel CSV format as well as related dictionaries. SAP, ICF, CSR information will be shared after the results are published.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: The IPD data will be available when the study is published in December 2026 and will remain for an additional year until December 2027.

Access criteria: The information may be requested by researchers who wish to carry out meta-analysis or researchers related to the area of secondary prevention of smoking. They may request it from the main or corresponding author who will review the applications.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Jan 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2024
First posted
Feb 12, 2024
StartActual
Jan 15, 2024
Primary completionEst.
Jan 15, 2025
CompletionEst.
Jun 15, 2026
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06254001
Lead sponsor
National Institute of Respiratory Diseases, Mexico
Responsible party
Ireri Thirion Romero (Principal Investigator, National Institute of Respiratory Diseases, Mexico) — Principal investigator
First posted
Feb 12, 2024
Start date
Jan 15, 2024
Primary completion
Jan 15, 2025 (estimated)
Completion
Jun 15, 2026 (estimated)
Last update
Feb 23, 2024

Study contacts

IRERI THIRION, DR
Contact
ireri.thirion@iner.gob.mx
55 5487 1700
ROGELIO PEREZ-PADILLA, DR
Contact
perezpad@gmail.com
55 5487 1700
IRERI THIRION-ROMERO, DR
principal investigator · INER

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupropion

Start the discussion